Conclusions
toxicity, cervical cancer, HPV-associated anogenital cancers, HPV-16/18 cancers
DISEASE, CERVICAL CANCER
The combination of MEDI0457 and durvalumab demonstrated acceptable safety and tolerability in patients with advanced HPV-16/18 cancers. The low ORR among patients with cervical cancer led to study discontinuation despite a clinically meaningful disease control rate.This article evaluates the anti-tumor activity and toxicity profile of the combination of MEDI0457 and durvalumab for patients with recurrent or metastatic HPV-associated anogenital cancers.